Skip to Main Content


  • Robert E. Hunter Professor of Therapeutic Radiology and Professor of Genetics; Chair, Therapeutic Radiology

    Research Interests
    • DNA Repair
    • Genetics
    • Radiation
    • Gene Targeting
    • Radiation Oncology
    • Recombinational DNA Repair
    • Gene Editing

Lab Members

  • Assistant Professor of Obstetrics and Gynecology; Head of Gynecologic Oncology Morbidity and Mortality , Obstetrics, Gynecology & Reproductive Sciences; Institutional Review Board Committee Member, Gynecologic Oncology

    Dr. Gary Altwerger is an assistant professor of Gynecologic Oncology in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the Yale School of Medicine. Known for his advanced surgical skills, Dr. Altwerger is an expert in minimally invasive techniques for treating uterine, ovarian, and vulvar cancers. His knowledge extends beyond the operating room to pioneering research in both clinical and basic sciences. He has identified biomarkers in advanced uterine cancer and developed strategies to disrupt tumor DNA repair pathways, advancing treatments for chemotherapy-resistant gynecologic cancers. Dr. Altwerger's basic science research on treatment resistant uterine cancers has led to the launch of an investigator-initiated clinical trial at Yale University. Additionally, his clinical research in evaluating desensitization protocols has enabled patients with hypersensitivities to receive effective yet previously intolerable chemotherapy treatments, with these findings published in high-impact gynecologic oncology journals. In the surgical arena, Dr. Altwerger has developed and published novel techniques for minimally invasive tumor removal in the upper abdomen. Additionally, as part of a mandate by the Department of Obstetrics, Gynecology, and Reproductive Sciences, he participates in the CSATS (Crowd-Sourced Assessment of Technical Skills) platform. This initiative utilizes national expert feedback to rate and enhance a surgeon’s operative skills. Reviews on CSATS often highlight Dr. Altwerger's surgical expertise, with feedback noting his 'clever' and 'expert' approaches to managing 'challenging' cases in gynecologic oncology. Dr. Altwerger’s commitment to professional development and excellence in gynecologic oncology is evident in his multifaceted role at Yale. He educates future medical professionals on gynecologic cancers and related topics, oversees the Inpatient Gynecologic Oncology Advanced Practice Providers, and chairs the Gynecologic Oncology Morbidity and Mortality meetings. Furthermore, he serves on the Institutional Review Board (IRB) at Yale New Haven Hospital, ensuring the safety and ethical standards of cancer research protocols. Clinically, he remains at the forefront of administering the latest therapies, including chemotherapies, immunotherapies, intraoperative chemotherapy and antibody-drug conjugates, to provide targeted care for women with gynecologic malignancies.
  • MD-PhD Student

    Daniel A. Colón Ríos was born and raised in Puerto Rico. He graduated in 2018 from Universidad de Puerto Rico - Recinto Universitario de Mayagüez (UPR-RUM) with a major in Chemistry. He subsequently moved to New Haven and joined Dr. Faye Rogers lab as a postgraduate associate, where he studied the cellular response to excessive levels of nucleotide-excision repair (NER)-recognized DNA damage. As a postgraduate associate, he also completed the Yale Cancer Center Cancer Biology Training Program (CBTP) and served as an interpreter at the HAVEN Free Clinic. Daniel is now a fourth year MD-PhD Student in the Glazer Lab studying PARP inhibitor resistance mechanisms. He is an active member of the MSTP Diversity, Equity and Inclusion Committee and continues to be involved in the Student National Medical Association - Latino Medical Student Association (SNMA-LMSA) joint chapter at Yale School of Medicine. Out of academics, Daniel enjoys spending time with friends, playing volleyball, going to the beach, and traveling.
  • Hospital Resident

    Hometown: Rockaway, NJ. Internship: General Surgery at Rutgers University Robert Wood Johnson Medical School in New Brunswick, NJ. Research Interests: Epigenetics, chromatin modifying enzymes, chromatin structure and repair, radiosensitizers. Outside Interests: Travel, hiking, live music, cooking, coffee, plants/gardening.
  • MD/PhD Student, Therapeutic Radiology

    A native of Kansas City, Anna graduated from the University of Kansas with a B.S. in Chemical Engineering. She joined the MD/PhD program at the Yale School of Medicine in 2017. Currently, Anna is conducting her graduate thesis work in the Department of Biomedical Engineering, where she is focused on in utero delivery of polymeric nanoparticles for fetal gene therapy. Anna’s clinical interests include adolescent gynecology, neonatal medicine, and fetal therapy.


Edward Gunther

Pre-doctoral, 1991-1993
Penn State College of Medicine, Harrisburg, PA
Triplex DNA and psoralen mutagenesis

Toni Yeasky

Research Assistant
Sr. Research Associate, Comprehensive Cancer Ctr. Sylvester Research Laboratories
University of Miami, Coral Gables, FL
Mutagenesis in the tumor microenvironment

Pamela Havre

Post-doctoral, 1992-1995
Research Assistant Professor, Dept. of Hematology & Oncology
University of Florida, Gainesville, FL
Targeted mutagenesis using triplex-forming oligonucleotides

Gan Wang

Post-doctoral, 1993-1996
Associate Professor, Institute of Environmental Health Science
Wayne State University, Detroit, MI
Mutagenesis and DNA repair induced by triplex-forming oligonucleotides

Elaine Lau

Undergraduate, 1994-1995
Postdoctoral Scholar, UCSF
Triplex DNA

Manidipa Mukherjee Raha

Post-doctoral, 1994-1997
Science teacher, Brookfield High School
Brookfield, CT
Mutagenesis in Xeroderma pigmentosum variant cells

A. Fawad Faruqi

Post-doctoral, 1994-1999
Senior Director Business Development
Discovery Life Sciences
Recombination induced by triplex formation

James Fritzell, Jr.

Research Assistant, 1995-1997
Neonatologist, Director of Transport, Director of Small Baby Program
MEDNAX, Long Beach, CA
Mutagenesis in transgenic mice

Bruce Turner

Post-doctoral, 1995-1998
Managing Director
Boxer Capital, Tavistock Group
Growth factors and radiation resistance

Philip Chan

Pre-doctoral, 1995-2000
CEO and President, CytoSorbents Corporation
Monmouth Junction, NJ
Targeted gene correction via triplex-forming oligonucleotides

Latha Narayanan

Research Technician, 1995-2003
Genetic instability in cancer cells

Laurent Lacroix

Pre-doctoral, 1996-1998
Staff Scientist, Museum National d'Histore Naturelle
Paris, France
Triplex formation by DNA analogs

Shilpi Mehta-Lee

Undergraduate, 1996-1998
Clinical Associate Professor, Department of Obstetrics & Gynecology
NYU Langone Health, New York, NY
Genetic instability in cancer cells

Karen Vasquez

Post-doctoral, 1996-2000
Professor, Division Head of Pharmacology & Toxicology
The University of Texas at Austin, Austin, TX
Gene targeting in mice using triplex-forming oligonucleotides

Shani Peretz

Pre-doctoral, 1996-2001
Department Chair, Science Department at Peddie School
Hightstown, NJ
Ataxia telangiectasia and regulation of IGF-1R expression

James Reddoch

Post-doctoral, 1997-1998
Executive Vice President and Head of Research
Royalty Pharma, New York, NY
Gene targeting with modified triplex-forming oligonucleotides

Jianling Yuan

Pre-doctoral, 1997-2003
Associate Professor, Radiation Oncology
University of Minnesota Hospital, Minneapolis, MN
Hypoxia and genetic instability

Melissa Knauert

Post-doctoral, 1997-2005
Assistant Professor of Medicine (Pulmonary)
Yale University, New Haven, CT
Targeted gene correction in vivo

Charlotte Kim

Post-doctoral, 1998-1999
Attending physician,
Div. of Radiation Oncology Dominican Santa Cruz Hospital
Santa Cruz, CA
Hypoxia and gene expression

Zhongjun John Luo

Post-doctoral, 1998-1999
Research Fellow, Department of Genetics and Medicine
Vanderbilt University, Nashville, TN
Recombination induced by triplex-forming oligonucleotides

Brady Dunklee

Lab Assistant, 1998-1999
Program Manager, Population Health at Integra Community Care Network
ATRAVES Inc., Providence RI
Mutagenesis in cancer cells

Xiaoxin Susan Xu

Post-doctoral, 1998-2000
Retired from Research Assistant Professor
Institute of Environmental Health Sci. Wayne State University,
Detroit, MI
DNA mismatch repair and genetic instability

Margaret Macris-Kiss

Pre-doctoral, 1998-2003
Head of Immunoassay Development at Ancera
Branford, CT
Transcription Gene targeting by triplex forming by oligonucleotides

Ming Zeng

Post-doctoral, 1999-2000
Director, Cancer Center
Sichuan Provincial People's Hospital, Chengdu, China
DNA mismatch repair and radiation response

Hirock Datta

Post-doctoral, 1999-2001
Group Leader at Zenotech Labs
Hyderabad Area, India
Triplex-induced recombination in vitro

Linda Gorman

Post-doctoral, 2000-2001
Project Coordinator at UBC- Envision Group
Southport, CT
Triplex-directed gene correction in the human beta globin gene

Ryan Jensen

Pre-doctoral, 2000-2004
Associate Professor, Department of Therapeutic Radiology
Yale University, New Haven, CT
DNA damage response and cell communication

Shannon Gibson Pankratz

Pre-doctoral, 2000-2005
Senior Scientist
Kolltan Pharmaceuticals, Vernon Rockville, CT
Ataxia telangiectasia and gene expression

Faye Rogers

Postdoctoral, 2000-2008
Associate Professor, Department of Therapeutic Radiology
Yale University, New Haven, CT
DNA repair of altered DNA structures

Valia Mihaylova

Post-doctoral, 2001-2004
Associate Research Scientist, Department of Laboratory Medicine
Yale University, New Haven, CT
Tumor hypoxia and DNA repair

Jean Kuan

Pre-doctoral 2001-2006
Chemical Sourcing Manager
Global Technical Operations, Alleran Inc., Irvine, CA
Triplex-directed gene correction in the human beta globin gene

Ranjit Bindra

Pre-doctoral, 2001-2007
Professor, Department of Therapeutic Radiology
Yale University, New Haven, CT
Tumor hypoxia and genetic instability

Janice Lloyd

Post-doctoral, 2002-2005
Scientist at U.S. Genomics
Woburn, MA
DNA repair

Ki-Hyun Kim

Postdoctoral, 2002-2008
Business Executive
Seoul, Korea
Gene targeting with peptide nucleic acids

Catherine Brdlik Hartman

Post-doctoral, 2005-2006
Director - UDENYCA & Therapeutic Oncology Product Development
San Mateo, CA
DNA Damage response and cell signaling

Pallavi Lonkar

Post-doctoral, 2005-2008
Director at Wave Life Sciences
Boston, MA
Gene targeting using chemically modified oligonucleotides

Joanna (Chin) Tansky

Pre-doctoral, 2005-2010
Assistant Professor, Department of Radiation Oncology
Massachusetts General Hospital, MA
Triplex DNA and DNA repair

Erica Schleifman

Pre-doctoral, 2006-2010
Senior Project Leader
Companion Diagnostics at Genentech
Gene targeting via DNA-binding molecules

Meredith Crosby

Post-doctoral, 2006-2011
AbbVie, North Chicago, IL
Hypoxia induced microRNAs and DNA repair

Elizabeth Peterson-Roth

Post-doctoral, 2006-2011
Staff Scientist, L2 Diagnostics
Yale University, New Haven, CT
Cisplatin and DNA damage response

Hanspeter Niederstrasser

Post-doctoral, 2008-2011
Screening Scientist
UTSouthwestern Medical Center, Dallas, TX
DNA repair of non-B form DNA

Faisal Reza

Post-doctoral, 2010-2013
Targeted Gene editing and Genome Engineering

Jennifer Kalish

Pre-doctoral, 2001-2006
Assistant Professor, Division of Human Genetics & Molecular Biology
The Children's Hospital of Philadelphia, Philadelphia, PA
Triplex DNA and DNA repair

James Hansen

Post-doctoral, 2011-2012
Associate Professor, Department of Therapeutic Radiology
Yale University, New Haven, CT
Novel antibody for cancer therapy

Nicole Ali McNeer

Pre-doctoral, 2010-2014
Fellow in Pediatric Hematology/Oncology
Memorial Sloan Kettering Cancer Center, NY
In vivo gene editing via nanoparticles

Jennifer Czochor

Pre-doctoral, 2010-2016
Senior Medical Director
BGB Group, Houston, TX
MicroRNA regulation and function in hypoxia

Nanda Balasubramanian

Post-doctoral, 2011-2016
Principal Clinical Bioanalytical Scientist
AstraZeneca, Cambridge, MA
Host factors required for triplex-mediated repair

Gregory Stachelek

Pre-doctoral, 2012-2016
Resident Physician
John Hopkins Medicine, Baltimore, MD
Novel DNA repair inhibitors for cancer therapy

Raman Bahal

Post-doctoral, 2012-2017
Assistant Professor, Pharmacology
University of Connecticut, Storrs, CT
Gene targeting with novel molecules

Susan Scanlon, MD, PhD

Pre-doctoral, 2018-2022
Resident in Therapeutic Radiology
Yale University, New Haven, CT
Hypoxia and DNA Repair

Audrey Turchick, PhD

Pre-doctoral, 2018-2019
Postdoctoral Scientist, TIP Oncology, DNA Damage Response Research Sub-team
EMD Serono, Rockland, MA
DNA Repair

Anisha Gupta, PhD

Post-doctoral, 2013-2017
Assistant Professor
Wesleyan University, Middletown, CT
Gene editing

Sebastian Oeck, PhD

Post-doctoral, 2017-2019
Post-doctoral Associate
University Hospital Essen, Essen, Germany
Oncometabolities and DNA Repair

Stanley Oyaghire, PhD

Post-doctoral, 2016-2019
Scientist at CRISPR Therapeutics
Cambridge, MA
Gene editing, cancer therapy, HIV therapy

Parker Sulkowski, PhD

Pre-doctoral, 2013-2019
Research Fellow at Kaelin Lab
Dana-Farber Cancer Institute, Boston, MA
Oncometabolities and DNA Repair

Adele Ricciardi, MD, PhD

Pre-doctoral, 2014-2019
Resident in Surgery
University of Pennsylvania, Philadelphia, PA
In utero gene editing

Alanna Kaplan, MD, PhD

Pre-doctoral, 2016-2019
Stanford Medicine, Stanford Health Care, Stanford, CA
Novel DNA repair inhibitors for cancer therapy

Jonathan Dow

Pre-doctoral, 2019-2022
ClearView Healthcare Partners
Newton, MA

Nicholas Economos

Pre-doctoral, 2017-2023
Brigham and Women’s Hospital
Boston, MA

Dinithi Perera

Post-doctoral, 2020-2023
Senior Scientist – Clinical Chemistry
New Haven, CT

Elias Quijano

Pre-doctoral, 2016-2023
Northpond Ventures
Gene editing and gene delivery